Assessment of familial risk in patients with hidradenitis suppurativa
- PMID: 33152101
- PMCID: PMC8035158
- DOI: 10.1111/bjd.19664
Assessment of familial risk in patients with hidradenitis suppurativa
Conflict of interest statement
Abbvie, Inc: speaker, co-investigator, and advisory board
Novartis: speaker, co-investigator
InflaRx: investigator, scientific advisory board
UCB: investigator
Chemocentryx: investigator
Figures

References
-
- Alikhan A, Sayed C, Alavi A, et al. North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management. Journal of the American Academy of Dermatology. 2019. - PMC - PubMed
-
- Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. Journal of the American Academy of Dermatology. 2014;71(3):460–467. - PubMed
-
- Cordell HJ, Olson JM. Correcting for ascertainment bias of relative-risk estimates obtained using affected-sib-pair linkage data. Genet Epidemiol. 2000;18(4):307–321. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical